Adarx Pharmaceuticals, A Leader In Next Generation Rna Therapeutics, Announces Oversubscribed $200 Million Series C Financing
Adarx Pharmaceuticals, A Leader In Next Generation Rna Therapeutics, Announces Oversubscribed $200 Million Series C Financing
08/09/23, 11:03 AM
Location
san diegoMoney raised
$200 million
Round Type
series c
Investors
Sr One Capital Management, Orbi Med, Lilly Asia Ventures, Ascenta Capital, Vivo Capital, Venrock Healthcare Capital Partners, T. Rowe Price Associates Inc., Redmile Group, Marshall Wace, Invus, Hbm Healthcare Investments, Cormorant Asset Management, Commodore Capital, Blackrock, Tcgx, Bain Capital Life Sciences
ADARx Pharmaceuticals, Inc. (“ADARx” or “the Company”), a clinical stage biotechnology company developing next generation RNA therapeutics, today announced the successful close of an oversubscribed $200 million Series C financing. The financing was led jointly by Bain Capital Life Sciences and TCGX and also included new investors Blackrock, Commodore Capital, Cormorant Asset Management, HBM Healthcare Investments, Invus, Marshall Wace, Redmile Group, T. Rowe Price Associates Inc., Venrock Healthcare Capital Partners, and Vivo Capital
Company Info
Location
5871 oberlin drive, suite 200
san diego, california, united states
Additional Info
ADARx Pharmaceuticals is a newly launched next-wave genetic medicine company focusing on oligonucleotide therapeutics for inhibition, degradation and base editing of mRNA transcripts. With RNA as the target of our drug discovery, we are capable of working on a wide range of diseases and are currently focusing on genetic, cardiometabolic, and central nervous system (CNS) diseases. We are driven by our mission to turn cutting-edge science into life-saving therapeutics and our desire to provide hope for patients with intractable disease.
We are well-financed with backup from a group of renowned VC funds, and our brand-new laboratory is located in San Diego, California.